New Path Molecular specialises in the chemical synthesis of complex functional molecules using the cutting edge techniques, methods and instrumentation developed in the laboratories of Prof Steve Ley at the University of Cambridge. Our processes and molecules are being used to validate biological processes and produce products globally.
Newgrange Consultants work with their clients to assess current leadership capabilities and to objectively evaluate development potential. We work with our clients to configure assessment processes appropriate to business circumstances and leadership selection and development scenarios including
- With investors, for pre-investment selection decisions and post-investment leadership development
- CEO, C-suite member, and senior executive effectiveness in current role
- Assessments for first time CEO appointments, including alignment to the chair, the board and the leadership team
- Assessment processes to support assessments across leadership teams
- Assessment of high potential emerging talent and future leaders for growth roles and development projects
- With investors, for pre-investment selection decisions and post-investment leadership development
- CEO, C-suite member, and senior executive effectiveness in current role
- Assessments for first time CEO appointments, including alignment to the chair, the board and the leadership team
- Assessment processes to support assessments across leadership teams
- Assessment of high potential emerging talent and future leaders for growth roles and development projects
In order to develop drugs to treat or prevent human disease a significant amount of complex scientific research needs to be done. Nexus BioQuest is a pre-clinical contract research organisation that collaborates with Biotechnology and Pharmaceutical companies in order to help accelerate their pre-clinical immunology research programmes. At our core we have: • Expertise- Deep immunology experience and knowledge in order to solve complex research problems. • Tempo- Agile and quickly expandable capability focused on reducing bureaucracy and burden so that collaborative science can thrive. • Collaboration- Be open and mutually trusting to maximise the impact of research and step away from a transactional approach. Our science will provide a comprehensive suite of solutions which will model the immune response depending on the research question being asked. These will form a pre-clinical package of assays including: • Relevant target expression. • Mode of action. • Efficacy. • Biomarkers. • Predictive immuno-toxicity. This will allow us to support our partners at multiple steps within the preclinical drug development process. All of our work is built on our deep understanding of the immune response, allowing us to provide relevant, customisable, cutting-edge assays, to advance our partners' drug development programs.
No data available
North Highland is the leading change and transformation consultancy providing management consulting services to the Fortune 1000 for over 30 years. Our industry practice teams work with the top global Life sciences companies in achieving their goals, from early-stage development, to manufacturing, supply chain, and commercialization. We provide consulting solutions across an array of industry challenges including enterprise transformation, digital & data science, workforce strategies, and omnichannel effectiveness. We bring a strong, collaborative team of experts to drive rapid value realization focused on rising above disruption and delivering business transformation. https://www.northhighland.com/
No data available
Nuclera is a US and UK-based biotechnology company driven by the mission to better human health by making proteins accessible. Nuclera is enabling life science researchers to obtain active proteins from DNA in 48 hours through its benchtop eProtein DiscoveryTM platform.
Website: https://www.nuclera.com
Contact: hello@nuclera.com
Watch our showcase video: https://www.nuclera.com/resource-library/video-intro-to-eprotein-discovery/
Website: https://www.nuclera.com
Contact: hello@nuclera.com
Watch our showcase video: https://www.nuclera.com/resource-library/video-intro-to-eprotein-discovery/
Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery. Our partners include Shire, AstraZeneca, MedImmune and Takeda. Our objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, depression, chronic insomnia, addiction, migraine and diabetes.
No data available
No data available